BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Interleukin-28A (IL-28A; IFNL2); interferon (IFN) λ receptor (IL28RA; IFNLR1)

May 14, 2015 7:00 AM UTC

Studies in mice suggest that IL-28A or IL28RA agonists could help treat RA and other neutrophil-mediated inflammatory diseases. IL28RA was highly expressed on circulating neutrophils in a mouse model of RA and healthy human donors. In the mouse model, IL-28A decreased neutrophil infiltration into synovial tissue, serum levels of pro-inflammatory interleukin-1 (IL-1) β and joint damage compared with vehicle. Next steps include testing IL-28A on human neutrophils...